<DOC>
	<DOC>NCT01680575</DOC>
	<brief_summary>To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.</brief_summary>
	<brief_title>Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients with FIGO stage IIV epithelial ovarian cancer after staging or debulking surgery Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin Patients who have signed approved informed consent Uncontrolled medical disease Active infectious disease Previous pelvic radiation therapy Previous chemotherapy (prospective cohort) Patients with disease which can cause neutropenia Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort). Pregnant or lactating woman</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Neutropenia</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Epithelial ovarian cancer</keyword>
</DOC>